Hong Kong
· Delayed Price · Currency is HKD Qyuns Therapeutics Statistics
Total Valuation
Qyuns Therapeutics has a market cap or net worth of HKD 2.23 billion. The enterprise value is 2.08 billion.
| Market Cap | 2.23B |
| Enterprise Value | 2.08B |
Important Dates
The next estimated earnings date is Friday, November 15, 2024.
| Earnings Date | Nov 15, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Qyuns Therapeutics has 222.07 million shares outstanding. The number of shares has increased by 20.04% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 222.07M |
| Shares Change (YoY) | +20.04% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 13.54% |
| Float | 106.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 33.36 |
| PB Ratio | 5.63 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -4.59 |
| EV / Sales | 32.45 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -9.54 |
Financial Position
The company has a current ratio of 1.86, with a Debt / Equity ratio of 1.38.
| Current Ratio | 1.86 |
| Quick Ratio | 1.65 |
| Debt / Equity | 1.38 |
| Debt / EBITDA | n/a |
| Debt / FCF | -2.46 |
| Interest Coverage | -18.65 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 197,278 |
| Profits Per Employee | -1.39M |
| Employee Count | 331 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 19.70 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 32.52 |
| Average Volume (20 Days) | 17,350 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Qyuns Therapeutics had revenue of HKD 64.12 million and -453.22 million in losses. Loss per share was -2.12.
| Revenue | 64.12M |
| Gross Profit | 56.42M |
| Operating Income | -458.15M |
| Pretax Income | -471.52M |
| Net Income | -453.22M |
| EBITDA | -425.42M |
| EBIT | -458.15M |
| Loss Per Share | -2.12 |
Balance Sheet
The company has 676.53 million in cash and 537.17 million in debt, giving a net cash position of 139.36 million or 0.63 per share.
| Cash & Cash Equivalents | 676.53M |
| Total Debt | 537.17M |
| Net Cash | 139.36M |
| Net Cash Per Share | 0.63 |
| Equity (Book Value) | 389.80M |
| Book Value Per Share | 1.78 |
| Working Capital | 354.32M |
Cash Flow
In the last 12 months, operating cash flow was -213.99 million and capital expenditures -4.12 million, giving a free cash flow of -218.11 million.
| Operating Cash Flow | -213.99M |
| Capital Expenditures | -4.12M |
| Free Cash Flow | -218.11M |
| FCF Per Share | -0.98 |
Margins
| Gross Margin | 88.00% |
| Operating Margin | -714.58% |
| Pretax Margin | -735.43% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -340.19% |
Dividends & Yields
Qyuns Therapeutics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.04% |
| Shareholder Yield | -20.04% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Qyuns Therapeutics has an Altman Z-Score of 1.92. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.92 |
| Piotroski F-Score | n/a |